Trial · NCT07906418
BCMA Polymorphisms in Patients With Multiple Myeloma
NCT07906418, Not yet recruiting, Başakşehir Çam & Sakura City Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. BCMA Polymorphisms in Patients With Multiple Myeloma. Trials, record NCT07906418. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906418
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- BCMA Polymorphisms in Patients With Multiple Myeloma
- NCT number
- NCT07906418
- Status
- Not yet recruiting
- Enrollment
- 420 participants, estimated
- Lead sponsor
- Başakşehir Çam & Sakura City Hospital
- Conditions
- Multiple Myeloma
- Interventions
- BCMA polymorphism analysis
- First posted
- 2026-10-30
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients achieving partial response or better after first-line induction therapy, by BCMA genotype | After 4 cycles of induction therapy (approximately 16 weeks from the start of treatment) | Treatment response will be assessed according to the International Myeloma Working Group (IMWG) 2016 response criteria. Patients achieving complete response, very good partial response, or partial response will be classified as responders, and those with stable or progressive disease as non-responders. The percentage of responders will be compared across BCMA (TNFRSF17) genotypes determined by next-generation sequencing. |
| Secondary | Progression-free survival (PFS) by BCMA genotype | From diagnosis to disease progression or death, assessed up to 144 months | PFS is defined as the time from diagnosis to documented disease progression according to IMWG criteria or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method, reported in months, and compared across BCMA (TNFRSF17) genotypes using the log-rank test. |
| Secondary | Overall survival (OS) by BCMA genotype | From diagnosis to death from any cause, assessed up to 144 months | OS is defined as the time from diagnosis to death from any cause. OS will be estimated using the Kaplan-Meier method, reported in months, and compared across BCMA (TNFRSF17) genotypes using the log-rank test. |
| Secondary | Frequency of BCMA genotypes in patients with multiple myeloma and healthy controls | At enrollment (single genotyping assessment) | Genotype frequencies of BCMA (TNFRSF17) polymorphisms, determined by next-generation sequencing, will be reported as the percentage of participants with each genotype and compared between patients with multiple myeloma and healthy controls. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906418
GET https://conductscience.org/api/trials/v1/NCT07906418/registered